Dengue virus 2 structural protein

Dengue virus 2 structural proteins are the components of the DENV2 virion responsible for genome encapsidation, assembly, and host cell entry[2][3]. The three principal structural proteins are the **Capsid (C) protein** (encapsidates viral RNA and participates in nucleocapsid formation), the **pre-membrane (prM) protein** (prevents premature fusion during assembly and is cleaved to form the membrane (M) protein), and the **Envelope (E) protein** (mediates attachment and fusion with host cells, and is a major target for neutralizing antibodies)[2][3]. Each protein is a critical and druggable target in the viral life cycle, but “Dengue virus 2 structural proteins” collectively is not a precise molecular target; rather, each structural protein (Capsid, prM/M, Envelope) is a specific target in itself[3]. The entry “Dengue virus 2 structural proteins” refers collectively to three proteins, not a single canonical molecular target, so is_incorrect is true according to your conventions. For true target-level granularity, split into the individual proteins: - Dengue virus capsid protein (C), abbreviation “DEN2C” - Dengue virus membrane protein (M), derived from prM - Dengue virus envelope protein (E) Drug interactions and mechanisms are tied to individual proteins: - ST-148 targets the capsid protein and inhibits virion assembly[3]. - Quercetin, Silymarin, Dapagliflozin, Fisetin, 3-110-22 target the envelope protein, mainly inhibiting viral entry or fusion[3]. - Neutralizing monoclonal antibodies bind E protein, blocking attachment or fusion[3]. Biomarkers: Serological assays detect antibodies to E protein, and viral antigen assays may target E or NS1 for diagnosis and monitoring[3]. Safety/therapeutic concerns: Drug resistance, viral variation, and the risk of antibody-dependent enhancement are prominent challenges in targeting DENV structural proteins[3].

Other names

Dengue virus structural proteinsDENV2 structural proteinsDengue virus capsid (C)Dengue virus pre-membrane protein (prM)Dengue virus envelope protein (E)

Inhibition of protein-RNA interactions (capsid), Blockade of membrane fusion (envelope protein E), Disruption of virion assembly or release (capsid), Antibody neutralization (envelope protein E)